{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:46:51Z","timestamp":1778856411133,"version":"3.51.4"},"reference-count":70,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Routine screening for monoclonal gammopathy of undetermined significance (MGUS) is not indicated. Despite this fact, MGUS is a common finding in medical practice. Almost all individuals diagnosed with MGUS represent incidental cases diagnosed when physicians order serum protein electrophoresis, immunofixation, or both, as part of the work-up of a number of common symptoms and laboratory abnormalities. In the absence of reliable molecular predictors of outcome, the detection of an early precursor state typically imposes a complex situation for the patient and the responsible physician\u2014usually, it leads to a lot of questions that lack clear answers. In the past years, several novel insights have been gained in the area of multiple myeloma (MM) precursor disease. This review focuses on results from recent investigations and discusses implications for diagnostic work-up, clinical management, and patient counseling. More specifically, it sheds light on the following commonly asked questions by patients and physicians: i) what is the risk of progression from precursor to full-blown MM, and are there ways to risk-stratify patients?; ii) is MM always preceded by a precursor state, and is there anything that could or should be done to delay or prevent progression?; and iii) why do some individuals develop MM precursor diseases, and is there a reason to screen the family?<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.295","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology"],"prefix":"10.1182","volume":"2010","author":[{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[{"name":"Multiple Myeloma Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111718012687500_B1","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect"},{"issue":"5","key":"2019111718012687500_B2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"6","key":"2019111718012687500_B3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"2019111718012687500_B4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111718012687500_B5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2019111718012687500_B6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance (MGUS) among African-American and Caucasian women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"key":"2019111718012687500_B7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"120","author":"Alexander","year":"2007","journal-title":"Int J Cancer"},{"issue":"11","key":"2019111718012687500_B8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1034\/j.1600-0463.2001.d01-149.x","article-title":"Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis","volume":"109","author":"Gregersen","year":"2001","journal-title":"Apmis"},{"issue":"12","key":"2019111718012687500_B9","first-page":"1697","article-title":"Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia","volume":"91","author":"Landgren","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"2019111718012687500_B10","first-page":"2978","article-title":"A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use","volume":"47","author":"Linet","year":"1987","journal-title":"Cancer Res"},{"issue":"12","key":"2019111718012687500_B11","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/ijc.21745","article-title":"Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study","volume":"118","author":"Landgren","year":"2006","journal-title":"Int J Cancer"},{"issue":"25","key":"2019111718012687500_B12","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111718012687500_B13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1289\/ehp.11318","article-title":"Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study","volume":"117","author":"Rusiecki","year":"2009","journal-title":"Environ Health Perspect"},{"issue":"9","key":"2019111718012687500_B14","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.24514","article-title":"Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden","volume":"125","author":"Kristinsson","year":"2009","journal-title":"Int J Cancer"},{"issue":"4","key":"2019111718012687500_B15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111718012687500_B16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111718012687500_B17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"key":"2019111718012687500_B18","volume-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"8","key":"2019111718012687500_B19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111718012687500_B20","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"issue":"26","key":"2019111718012687500_B21","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111718012687500_B22","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111718012687500_B23","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian","year":"1988","journal-title":"Arch Intern Med"},{"issue":"1","key":"2019111718012687500_B24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","article-title":"Risk of disease progression in asymptomatic multiple myeloma","volume":"94","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"issue":"2","key":"2019111718012687500_B25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","article-title":"Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma","volume":"87","author":"Witzig","year":"1994","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111718012687500_B26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11864-000-0056-3","article-title":"Smoldering, asymptomatic stage 1, and indolent myeloma","volume":"1","author":"Greipp","year":"2000","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"2019111718012687500_B27","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"issue":"5","key":"2019111718012687500_B28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111718012687500_B29","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2019111718012687500_B30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111718012687500_B31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019111718012687500_B32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111718012687500_B33","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111718012687500_B34","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/028418600750063578","article-title":"Imaging of myeloma bone disease\u2013implications for staging, prognosis and follow-up","volume":"39","author":"Dimopoulos","year":"2000","journal-title":"Acta Oncol"},{"issue":"9","key":"2019111718012687500_B35","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2019111718012687500_B36","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111718012687500_B37","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"25","key":"2019111718012687500_B38","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111718012687500_B39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111718012687500_B40","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111718012687500_B41","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111718012687500_B42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2019111718012687500_B43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111718012687500_B44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V114.22.614.614","article-title":"Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (Len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis paper [abstract]","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111718012687500_B45","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111718012687500_B46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4065\/82.4.428","article-title":"Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size","volume":"82","author":"Rosinol","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"2019111718012687500_B47","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/leu.2008.203","article-title":"Pathogenesis and progression of monoclonal gammopathy of undetermined significance","volume":"22","author":"Blade","year":"2008","journal-title":"Leukemia"},{"issue":"22","key":"2019111718012687500_B48","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111718012687500_B49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2019111718012687500_B50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/erm.10.31","article-title":"Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis","volume":"10","author":"Balakumaran","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"2019111718012687500_B51","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111718012687500_B52","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111718012687500_B53","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"2019111718012687500_B54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111718012687500_B55","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2019111718012687500_B56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2008.004440","article-title":"Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2019111718012687500_B57","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111718012687500_B58","first-page":"729","article-title":"Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma","volume":"130","author":"Rosinol","year":"2005"},{"issue":"10","key":"2019111718012687500_B59","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"issue":"25","key":"2019111718012687500_B60","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1200\/JCO.2008.19.1916","article-title":"Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma","volume":"27","author":"Anguiano","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111718012687500_B61","first-page":"5","article-title":"Immunophenotyping of plasma cells in multiple myeloma","volume":"113","author":"Mateo Manzanera","year":"2005","journal-title":"Methods Mol Med"},{"issue":"17","key":"2019111718012687500_B62","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-09-0040","article-title":"Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma","volume":"15","author":"Ria","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111718012687500_B63","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.beha.2007.08.002","article-title":"The malignant clone and the bone-marrow environment","volume":"20","author":"Podar","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6219","key":"2019111718012687500_B64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","article-title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia","volume":"339","author":"Folkman","year":"1989","journal-title":"Nature"},{"issue":"7","key":"2019111718012687500_B65","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111718012687500_B66","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1078-0432.CCR-08-2310","article-title":"Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation","volume":"15","author":"Hillengass","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111718012687500_B67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"issue":"35","key":"2019111718012687500_B68","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111718012687500_B69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.blre.2007.01.002","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"21","author":"Rajkumar","year":"2007","journal-title":"Blood Rev"},{"key":"2019111718012687500_B70","article-title":"SEER Cancer Statistics Review, 1975\u20132005, based on November 2007 SEER data submission","author":"Ries","year":"2008"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/295\/1492973\/bep00110000295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/295\/1492973\/bep00110000295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T13:47:13Z","timestamp":1637156833000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/295\/96391\/Monoclonal-Gammopathy-of-Undetermined-Significance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.295","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}